市場調查報告書

登革熱檢驗的全球市場:成長,趨勢,及預測

Dengue Testing Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921264
出版日期 內容資訊 英文 110 Pages
商品交期: 2-3個工作天內
價格
登革熱檢驗的全球市場:成長,趨勢,及預測 Dengue Testing Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 110 Pages
簡介

登革熱檢驗的全球市場,由於增加登革熱負擔的可能性高的氣候變化,及提高登革熱的認識的提高認識宣傳活動的增加,預計急速成長。從新興國家回國的旅客中,登革熱是次於瘧疾第2大確診的發熱原因。因此,由於登革熱病毒的盛行率上升,更多的診斷套件的需求高漲,預計不久將來帶動該市場。還有歐洲各國的氣候也有變化,對媒介生物的分佈和潛在疾病傳染帶來很大的影響。該氣候變化恐怕增加登革熱的負擔高,可能成為今後市場成長要素。

本報告提供全球登革熱檢驗市場的相關調查,市場機會和趨勢,成長及阻礙因素,各產品類型、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 提高登革熱病例的發生率
    • 氣候的變化增加登革熱的負擔的可能性高
    • 為了教育登革熱疾病提升認識宣傳活動
  • 阻礙市場要素
    • 有效的診斷工具的不利用性
    • 現有的檢測套組的高價格
  • 波特的五力分析

第5章 市場區隔

  • 各產品類型
    • ELISA為基礎的檢驗
    • RT-PCR為基礎的檢驗
    • 登革熱IgG / IgM迅速檢驗
    • 其他
  • 各終端用戶
    • 醫院
    • 診斷中心
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • InBios International, Inc.
    • NovaTec Immundiagnostica GmbH
    • Euroimmun AG (Sub. PerkinElmer)
    • Quest Diagnostics
    • Certest Biotec SL
    • OriGene Technologies
    • Abnova Corporation

第7章 市場機會及今後趨勢

目錄
Product Code: 67161

Market Overview

The dengue testing market will show rapid growth due to the increasing incidences of dengue cases, change in climate is likely to increase the burden of dengue fever and increasing awareness campaigns to educate about the ills of dengue.

The overall incidence of dengue, as well as the explosive outbreaks of dengue, has been increasing dramatically over the last several years. According to the World Health Organization, the number of cases reported has increased from 2.2 million in 2010 to over 3.34 million in 2016. Although the full global burden of the disease is uncertain, the initiation of activities to record all dengue cases partly explains the sharp increase in the number of cases reported in recent years. Therefore not only the number of cases is increasing as the disease spreads to new areas, but explosive outbreaks are occurring. Among travelers returning from low- and middle-income countries, dengue is the second most diagnosed cause of fever after malaria. Therefore the rising prevalence of dengue virus has raised the demand for more diagnostic kits, which is expected to drive the dengue testing market in the near future.

There is also a change in the climate of European countries, that has been a great impact on the vector distribution and potential disease transmission. This change in climate is likely to increase the burden of dengue fever, and this, in turn, will propel the growth of the market of dengue testing.

Scope of the Report

As per the scope of the report, dengue is the most rapidly spreading mosquito-borne viral disease in the world. Blood testing detects the dengue virus or antibodies produced in response to dengue infection. Therefore to control the spread of dengue fever there are various diagnostic tests introduced to reduce the number of deaths and focus on prevention and cure.

Key Market Trends

ELISA-Based Tests is Expected to Dominate the Product Type Segment During the Forecast Period

The most widely used method for diagnosing dengue is an enzyme-linked immunosorbent assay (ELISA) which measures anti-DENV IgM or IgG antibodies in patient serum. The early diagnosis and management of dengue help to reduce the morbidity and mortality rates of severe forms of dengue disease as well as decrease the risk of wider outbreaks.

The enzyme-linked immunosorbent assay (ELISA) is capable of detecting NS1 antigens and differentiating among the four dengue virus serotypes. ELISA kits are found to have superior sensitivity when compared to RDTs. Because of their superior performance, ELISAs would be the recommended diagnostic choice when laboratories with trained personnel and equipment are available.

The Asia Pacific is Found Leading the Dengue Testing Market

Asia pacific is found to be leading in the global dengue testing market as there are millions of cases of dengue infection every year. In India, there have been more than 300 percent hike in the dengue cases since 2009 and even the total number of deaths in 2017 was the highest in the last decade. Dengue fever is most common in Southeast Asia and the disease has been increasing rapidly. There are also several research organizations that have shown interest in developing new lines of medication for treating dengue.

The market for dengue testing in the Asia Pacific is thus expanding at a fast pace on account of the rising incidence of infectious diseases, including dengue, in India, Pakistan, and Sri Lanka.

Competitive Landscape

There has been a presence of a considerable number of companies that are significantly contributing to market growth. Recently the Telenor Heath's Tonic has launched the "Home Diagnostic Tests" service for dengue with video consultation through their "Tonic App". The major companies that are functioning in the global dengue testing market include Abbott Laboratories, NovaTec Immundiagnostica GmbH, Euroimmun AG (PerkinElmer), Quest Diagnostics, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., and InBios International, Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increase Incidences of Dengue Cases
    • 4.2.2 Change in Climate is Likely to Increase the Burden of Dengue Fever
    • 4.2.3 Increasing Awareness Campaigns to Educate About the Ills of Dengue
  • 4.3 Market Restraints
    • 4.3.1 Unavailability of Effective Diagnostic Tools
    • 4.3.2 High Price of Existing Test Kits
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 ELISA-based Tests
    • 5.1.2 RT-PCR based Tests
    • 5.1.3 Dengue IgG/IgM Rapid Test
    • 5.1.4 Other Tests
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Diagnostic Centers
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Thermo Fisher Scientific Inc.
    • 6.1.2 F. Hoffmann-La Roche Ltd.
    • 6.1.3 Abbott Laboratories
    • 6.1.4 InBios International, Inc.
    • 6.1.5 NovaTec Immundiagnostica GmbH
    • 6.1.6 Euroimmun AG (Sub. PerkinElmer)
    • 6.1.7 Quest Diagnostics
    • 6.1.8 Certest Biotec S.L.
    • 6.1.9 OriGene Technologies
    • 6.1.10 Abnova Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS